Español | Other Languages



HIV HIV Home



Core Indicators for Monitoring the Ending the HIV Epidemic Initiative (Preliminary Data): National HIV Surveillance System Data Reported through June 2023; and Preexposure Prophylaxis (PrEP) Data Reported through March 2023

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through June 2023 and preexposure prophylaxis (PrEP) data reported through March 2023.

HIV Surveillance Data Tables is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

Suggested Citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through June 2023; and preexposure prophylaxis (PrEP) data reported through March 2023. *HIV Surveillance Data Tables 2023*;4(3). https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/. Published October 2023. Accessed [date].

On the Web: https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/

Confidential information, referrals, and educational material on HIV infection CDC-INFO 1-800-232-4636 (in English, en Español) 1-888-232-6348 (TTY) http://wwwn.cdc.gov/dcs/ContactUs/Form

Acknowledgments

HIV Surveillance Data Tables was prepared by the following staff and contractors of the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC: Juliet Morales, Anna Satcher Johnson, Zanetta Gant Sumner, Ya-lin Huang, Weiming Zhu, Emily Zhu, Pei Hou, Chelsea Walker, Chan Jin, Thanh Chau Pham, Xueyuan Dong, Nan Hong, Lei Yu, Wei Wei, Eli Krebs, Norma Harris, Stacy Cohen, and Michael Friend (editing).

The Content and Infrastructure Team of the Prevention Communications Branch are acknowledged for their contributions to the report website.

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

Tachaical Niatac

ופנוווונמו ואטנפא

The Ending the HIV Epidemic in the U.S. (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and by 90% by 2030. The Centers for Disease Control and Prevention (CDC) routinely releases *HIV Surveillance Data Tables* on the core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the *Core Indicators for Monitoring the Ending the HIV Epidemic Initiative* report, available at https://www.cdc.gov/hiv/pdf/library/reports/surveillance-data-tables/vol-1-no-1/cdc-hiv-surveillance-tables-vol-1-no-1.pdf

The tables included in this report provide preliminary data on HIV diagnoses and linkage to HIV medical care for the years 2022 and 2023 based on cases reported to CDC as of June 2023. Data on preexposure prophylaxis (PrEP) coverage are provided for the years 2019, 2020, 2021, 2022, and 2023 (preliminary). Data for the 3 indicators are provided at the national, state, and county levels (EHE Phase I jurisdictions only). See Tabulation and Presentation of Data for details on how the indicators are calculated.

Tabulation and Presentation of Data Diagnoses of HIV Infection

Diagnoses of HIV infection are the numbers of persons aged \geq 13 years with HIV diagnosed during January 2022 through June 2023 (Tables 1a–d). Data presented were reported (after the removal of personally identifiable information) to CDC.

An evaluation of surveillance data (2016–2020 diagnoses) found that, on average, approximately 80% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 98% of HIV diagnoses are reported to CDC by the end of the following year. Data for years 2022 and 2023 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on counting diagnoses of HIV infection can be found in the *HIV Surveillance Report, 2021*, available at https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-34/index.html.

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged \geq 13 years whose infection was diagnosed during January 2022 through March 2023 and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 2a–c). The numerator is the number of persons aged \geq 13 years whose HIV infection was diagnosed during January 2022 through March 2023 and who had \geq 1 CD4 T-lymphocyte (CD4) or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged \geq 13 years whose HIV infection was diagnosed during January 2022 through March 2023. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons whose HIV infection was diagnosed during January 2023 and reported to NHSS through June 2023. Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

More information on calculating linkage to care can be found in Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2021, available at https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-28-no-4/index.html.

Preexposure Prophylaxis (PrEP) Coverage

PrEP coverage, reported as a percentage, is defined as the number of persons aged \geq 16 years classified as having been prescribed PrEP during the specified year divided by the estimated number of persons aged \geq 16 years who had indications for PrEP during the specified year (Tables 3a–c). PrEP coverage is an EHE indicator that is not a reportable disease or condition and is not reported to NHSS. Multiple data sources, described below, are used to calculate PrEP coverage. Please note that changes in the total percentage across each report are because data are received at multiple points through the year; readers should note the period for which the data are calculated and use caution when comparing partial year data to full year data.

Please use caution when interpreting PrEP data. Different data sources were used in the numerator and denominator to calculate PrEP coverage.

Persons prescribed PrEP

National pharmacy data from the IQVIA Real World Data—Longitudinal Prescriptions database (hereafter, IQVIA database) are used to classify persons aged ≥16 years who have been prescribed PrEP in the specific year. The IQVIA database captures prescriptions from all payers and represents approximately 94% of all prescriptions from retail pharmacies and 74% from mail-order outlets in the United States. The database does not include prescriptions from some closed health care systems that do not make their prescription data available to IQVIA. Therefore, these are minimum estimates of PrEP coverage. The annual number of persons classified as having been prescribed PrEP was based on a validated algorithm that discerns whether tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) was prescribed for PrEP after excluding prescriptions for HIV treatment, hepatitis B treatment, or HIV postexposure prophylaxis [2–4]. Tenofovir alafenamide and emtricitabine (TAF/FTC) was approved as an alternative drug for PrEP by the U.S. Food and Drug Administration (FDA) in October 2019. Long-acting injectable cabotegravir (CAB-LA) was approved by the FDA as an additional prevention option for PrEP in December 2021. After the respective approvals, TAF/FTC and CAB-LA were included in the algorithm to classify the number of persons prescribed PrEP.

The number of persons classified as having been prescribed PrEP is reported by sex, age group, and race/ethnicity. Transmission category data are not available in the IQVIA database, and race/ethnicity data are available for <40% of persons with PrEP prescriptions. Please use caution when interpreting PrEP data by race/ethnicity. Race/ethnicity categories available in the IQVIA database include White, Black/African American, Hispanic/Latino, and other. The number of persons prescribed PrEP for each racial/ethnic group presented in this report was extrapolated by applying the racial/ethnic distribution of known records to those for which data on race/ethnicity were unknown.

Geographic Designations

In the IQVIA database, a person's location is reported as a 3-digit ZIP code prefix (hereafter, ZIP3) assigned by the U.S. Postal Service. To estimate the number of persons prescribed PrEP at the state or county level, a probability-based approach is used to crosswalk between ZIP3s and states/counties by using data from (a) the U.S. Census Bureau's

American Community Survey (ACS) 5-year estimates by ZIP Code Tabulation Areas (ZCTAs) [5], and (b) the U.S. Department of Housing and Urban Development's ZIP Code Crosswalk Files [6]. Because of reliability concerns, subnational estimates of <40 are not included.

Persons with PrEP indications

U.S. Census Bureau files and their ACS were used to estimate the number of gay, bisexual, and other men who have sex with men (MSM) in a jurisdiction [7, 8]. Next, behavioral data from the National Health and Nutrition Examination Survey (NHANES) were used to estimate the proportion of HIV-negative MSM with indications for PrEP [9].

The number of HIV-negative MSM with indications for PrEP was multiplied by the ratio of percentage of diagnoses during the specified year attributed to other major transmission risk groups compared to the percentage among MSM in a given state or county. The estimated numbers of persons with indications for PrEP in the 3 major transmission risk groups (MSM, heterosexuals, persons who inject drugs) in each jurisdiction were then summed to yield a state- or county-specific estimate. State estimates were then summed for a national total of persons with indications for PrEP [7]. Jurisdictional estimates were rounded to the nearest 10.

The tables included in this report provide updated data on PrEP coverage for the years 2019–2023 by using the IQVIA data reported through March 2023. IQVIA conducts data quality assurance activities. As a result, the number of persons classified as having been prescribed PrEP in a given year might change from time to time. The impact of the changes may vary by demographic category nationally and by jurisdiction. The data sources used to estimate the number of persons with indications for PrEP have different schedules of availability. Consequently, the availability of a denominator lags the availability of a numerator. PrEP coverage data with a lagged denominator are considered preliminary.

For this release of HIV Surveillance Data Tables, 2018 denominators were used for 2019 through 2023 PrEP coverage data; consequently, 2019 through 2023 PrEP coverage data are considered preliminary. In addition to being preliminary, data for the year 2020 should be interpreted with awareness of the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions [10].

More information on calculating PrEP coverage can be found in Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2021, available at https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.

References

- 1. HHS. What is Ending the HIV Epidemic in the U.S.? Available at https://www.hiv.gov/federal-response/ending-thehiv-epidemic/overview ☑ . Updated July 2, 2022. Accessed September 1, 2023.
- 2. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014 Clin Infect Dis 2017;64(2):144–149. doi:10.1093/cid/ciw701
- 3. CDC [Huang YA, Zhu W, Smith DK, Harris N, Hoover KW]. HIV preexposure prophylaxis, by race and ethnicity— United States, 2014–2016. *MMWR* 2018;67(41):1147–1150. doi:10.15585/mmwr.mm6741a3

- 7. Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the population sizes of men who have sex with men in US states and counties using data from the American Community Survey ☑ . *JMIR Public Health Surveill* 2016;2(1):e14. doi:10.2196/publichealth.5365
- 8. Purcell DW, Johnson CH, Lansky A, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates ☑ . Open AIDS J 2012;6:98–107. doi:10.2174/1874613601206010098
- CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. MMWR 2015;64(46):1291–1295. doi:10.15585/mmwr.mm6446a4
- Huang YA, Zhu W, Wiener J, Kourtis AP, Hall HI, Hoover KW. Impact of coronavirus disease (COVID-19) on human immunodeficiency virus (HIV) pre-exposure prophylaxis prescriptions in the United States—a time series-analysis
 Clin Infect Dis 2022:75(1):e1020–e1027. doi:10.1093/cid/ciac038

Table 1a. Diagnoses of HIV infection among persons aged ≥13 years, by selected characteristics, January 2022 through June 2023—United States (*preliminary*)

	2022	2023 (January–June)
	No.	No.
Gender		
Male	29,578	12,676
Female	6,942	2,943

Transgender woman ^a	810	240
Transgender man ^a	53	22
Additional gender identity ^b	66	31
Age at diagnosis (yr)		
13-24	6,895	2,723
25-34	13,956	5,727
35-44	8,265	3,742
45-54	4,580	1,995
≥55	3,753	1,725
Race/ethnicity		
American Indian/Alaska Native	222	77
Asian	802	310
Black/African American	14,660	6,512
Hispanic/Latino ^c	11,631	4,680
Native Hawaiian/other Pacific Islander	83	25
White	9,187	4,062
Multiracial	864	246
Transmission category ^d		
Male-to-male sexual contact ^e	25,218	10,793
Injection drug use ^f		
Male	1,427	569
Female	1,168	408
Male-to-male sexual contact ^e and injection drug use ^f	1,288	473
Heterosexual contact ^g		
Male	2,477	1,092
Female	5,750	2,529
Other ^h		
Male	39	18
Female	82	30
Region of residence		
Northeast	5,053	1,756
Midwest	4,833	2,133
South	19,966	9,240
West	7,597	2,783
Total	37,449	15,912

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through June 2023. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

^a"Transgender woman" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender. "Transgender man" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender. ^bAdditional gender identity examples include "bigender," "gender queer," and "two-spirit."

^cHispanic/Latino persons can be of any race.

^dTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^eIncludes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact). ^fIncludes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers). ^gHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.

^hOther risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 1b. Diagnoses of HIV infection among persons aged ≥13 years, by selected characteristics, January 2022 through June 2023—United States and 6 dependent areas *(preliminary)*

	2022	2023 (January–June)
	No.	No.
Gender		
Male	29,885	12,791
Female	7,005	2,962
Transgender woman ^a	812	240
Transgender man ^a	53	22
Additional gender identity ^b	66	31
Age at diagnosis (yr)		
13-24	6,944	2,732
25-34	14,081	5,775
35-44	8,344	3,769
45-54	4,642	2,020
≥55	3,810	1,750
Race/ethnicity		
American Indian/Alaska Native	222	77
Asian	802	310

Black/African American	14,666	6,513						
Hispanic/Latino ^c	11,987	4,809						
Native Hawaiian/other Pacific Islander	83	25						
White	9,197	4,065						
Multiracial	864	247						
Transmission category ^d								
Male-to-male sexual contact ^e	25,444	10,874						
Injection drug use ^f								
Male	1,451	577						
Female	1,174	408						
Male-to-male sexual contact ^e and injection drug use ^f	1,295	474						
Heterosexual contact ^g								
Male	2,529	1,117						
Female	5,806	2,548						
Other ^h								
Male	40	18						
Female	83	31						
Region of residence								
Northeast	5,053	1,756						
Midwest	4,833	2,133						
South	19,966	9,240						
West	7,597	2,783						
U.S. dependent areas	372	134						
Total	37,821	16,046						

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through June 2023, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

^a"Transgender woman" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender. "Transgender man" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender. ^bAdditional gender identity examples include "bigender," "gender queer," and "two-spirit."

^cHispanic/Latino persons can be of any race.

^dTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^eIncludes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact). ^fIncludes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers). ^gHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.

^hOther risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 1c. Diagnoses of HIV infection among persons aged ≥13 years, by area of residence, January 2022 through June 2023—United States and 6 dependent areas *(preliminary)*

	2022	2023 (January–June)
Area of residence	No.	No.
Alabama	518	174
Alaska	38	14
Arizona	899	439
Arkansas	306	191
California	4,577	1,468
Colorado	429	192
Connecticut	225	62
Delaware	128	43
District of Columbia	188	30
Florida	4,513	2,786
Georgia	2,687	1,062
Hawaii	70	13
Idaho	43	16
Illinois	1,270	398
Indiana	622	289
Iowa	120	70
Kansas	136	62
Kentucky	406	191
Louisiana	856	423
Maine	40	17
Maryland	745	278
Massachusetts	435	50
Michigan	631	345
Minnesota	262	145

Mississippi	426	145
Missouri	504	238
Montana	10	6
Nebraska	90	41
Nevada	533	215
New Hampshire	28	12
New Jersey	1,096	315
New Mexico	73	9
New York	2,205	883
North Carolina	1,360	678
North Dakota	10	1
Ohio	859	387
Oklahoma	392	111
Oregon	249	104
Pennsylvania	954	395
Rhode Island	66	15
South Carolina	770	430
South Dakota	39	18
Tennessee	861	394
Texas	4,840	1,853
Utah	151	54
Vermont	4	7
Virginia	831	408
Washington	511	247
West Virginia	139	43
Wisconsin	290	139
Wyoming	14	6
Subtotal	37,449	15,912
U.S. dependent areas		
American Samoa	0	0
Guam	0	0
Northern Mariana Islands	0	0
Puerto Rico	358	130
Republic of Palau	0	0
U.S. Virgin Islands	14	4
Subtotal	372	134
Total	37,821	16,046

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at the time of diagnosis of HIV infection. Data are for cases reported to CDC through June 2023, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 1d. Diagnoses of HIV infection among persons aged ≥13 years, by area of residence, January 2022 through June 2023—Ending the HIV Epidemic Phase I jurisdictions *(preliminary)*

	2022	2023 (January–June)
Area of residence	No.	No.
Arizona		
Maricopa County	592	304
California		
Alameda County	201	81
Los Angeles County	1,429	479
Orange County	252	112
Riverside County	308	82
Sacramento County	190	36
San Bernardino County	281	83
San Diego County	378	38
San Francisco County	213	81
District of Columbia	188	30
Florida		
Broward County	608	394
Duval County	288	171
Hillsborough County	297	213
Miami-Dade County	1,096	665
Orange County	430	266
Palm Beach County	297	144
Pinellas County	116	105
Georgia		
Cobb County	199	77
DeKalb County	378	133
Fulton County	585	203

Gwinnett County	209	87
Illinois		
Cook County	853	263
Indiana		
Marion County	252	110
Louisiana		
East Baton Rouge Parish	132	67
Orleans Parish	126	58
Maryland		
Baltimore City	157	60
Montgomery County	106	41
Prince George's County	253	79
Massachusetts		
Suffolk County	115	20
Michigan		
Wayne County	247	132
Nevada		
Clark County	487	189
New Jersey		
Essex County	234	59
Hudson County	168	48
New York		
Bronx County	394	146
Kings County	475	173
New York County	320	121
Queens County	368	145
North Carolina		
Mecklenburg County	279	149
Ohio		
Cuyahoga County	119	68
Franklin County	195	92
Hamilton County	94	45
Pennsylvania		
Philadelphia County	378	171
Puerto Rico		
San Juan Municipio	111	33

Tennessee

Shelby County	338	138					
Texas							
Bexar County	347	96					
Dallas County	880	351					
Harris County	1,275	545					
Tarrant County	335	124					
Travis County	243	109					
Washington							
King County	267	141					

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at the time of diagnosis of HIV infection. Data are for cases reported to CDC through June 2023, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2022 through March 2023—47 states and the District of Columbia (*preliminary*)

2022					20	23 (Janua	ary–Ma	rch)	
Total diagnoses	Total diagnoses≥1 CD4 ∪r VL testsNo.No.%		No CD4 or VL test		Total diagnoses	≥1 CD4 test	or VL s	No CD4 tes	or VL t
No.			No. %		No.	No.	%	No.	%
Gender									
27,926	22,866	81.9	5,060	18.1	7,535	6,182	82.0	1,353	18.0
6,533	5,228	80.0	1,305	20.0	1,714	1,387	80.9	327	19.1
782	653	83.5	129	16.5	160	143	89.4	17	10.6
50	46	92.0	4	8.0	12	12	100	0	0.0
65	61	93.8	4	6.2	18	17	94.4	1	5.6
6,578	5,301	80.6	1,277	19.4	1,634	1,297	79.4	337	20.6
13,123	10,690	81.5	2,433	18.5	3,407	2,795	82.0	612	18.0
7,774	6,375	82.0	1,399	18.0	2,234	1,830	81.9	404	18.1
4,344	3,557	81.9	787	18.1	1,212	1,012	83.5	200	16.5
3,537	2,931	82.9	606	17.1	952	807	84.8	145	15.2
	Total diagnoses No. 27,926 6,533 782 50 6,578 13,123 7,774 4,344 3,537	Total diagnoses \$1 CD4 cest No. \$1 CD4 cest No. No. No. No. 127,926 22,866 127,927 22,866 127,928 5,228 120,020 10,603 120,020 10,600 131,123 10,690 13,124 3,557 13,537 2,931	2022Total diagnoses\$1 CD4 vL testNo.\$1 CD4 vL testNo.\$1 CD4 vL testNo.\$1 CD4 vL testNo.\$1 CD4 vL test1000\$1 CD4 vL 	2022Total diagnoses\$1 CD2 + VL testNo CD2 testNo.No.%No.No.No.%No.No.No.%No.10022,86681.95,0601015,22880.01,30510265335,22880.01,3051035,22880.01,305103653383.51291036192.041036193.81,2771035,30180.61,3931035,30181.91,3931033,55781.97,8741032,93182.9606	2022Total diagnoses\$1 CD2 + VL textNo CJ2+VL textNo.No.%No.%No.No.%No.%No.22,86681.95,06018.1127,92622,86880.01,30020.0166,5335,22880.01,30020.0167,73665.083.01,30016.1167,7576.6192.01,2436.1163,75781.01,2431,81.0163,75781.01,31.01,81.1163,5372,93182.96.061,71.1	2022SolutionSolutionTotal diagnoses1CTotal diagnosesNo.%No.%No.ModelNo.%No.%No.%No.%No.%No.%No.%No.%No.%No.%No.%No.%No.%%No.%No.StateState%No.%%State%%%%%State%%%%%State%%%%%State%%%%%State%%%%%State%%%%%State%%<	DescriptionTotal diagnoses\$1 CD2 + V testNo CD4 + V diagnosesTotal diagnoses\$1 CD2 + V secNo.No.NoNoNo.MoNo.No.No.No.No.No.StorStorStorNo.No.No.2000No.No.StorStorStorStorStorStorNo.20112020StorStorStorStorStorStorStorStor20122020StorStorStorStorStorStorStorStor20132020StorStorStorStorStorStorStor2014StorStorStorStorStorStorStor2015StorStorStorStorStorStorStor2016StorStorStorStorStorStorStor2017StorStorStorStorStorStorStor2018StorStorStorStorStorStorStor2019StorStorStorStorStorStorStor2019StorStorStorStorStorStorStor2019StorStorStorStorStorStorStor2019StorStorStorStorStorStorStor2019StorStorStor </td <td>DescriptionTotal diagnoses1 CD2 + V testNo CD2 + V clagnosesTotal diagnoses1 CD2 + V testNo.1 CD2 + V testNo CD2 + V clagnosesNo.1 CD2 + V testNo.No.No.10No.10No.10No.No.No.100100100100100100100100010201030103010301030103010301030103010101020103010301030103010301030103010301010103010301030103010301030103010301030101010301030103010301030103010301030103010101030103010301030103010301030103010301010103010301030103010301030103010301030101010301030103010301030103010301030103010101030103010301030103010301030103010301010103010301030103010301030103010301030101010301030103010301030103010301030103010101030103010301030103010301030<</td> <td>IDENTIFY<th colspan="6</td></td>	DescriptionTotal diagnoses1 CD2 + V testNo CD2 + V clagnosesTotal diagnoses1 CD2 + V testNo.1 CD2 + V testNo CD2 + V clagnosesNo.1 CD2 + V testNo.No.No.10No.10No.10No.No.No.100100100100100100100100010201030103010301030103010301030103010101020103010301030103010301030103010301010103010301030103010301030103010301030101010301030103010301030103010301030103010101030103010301030103010301030103010301010103010301030103010301030103010301030101010301030103010301030103010301030103010101030103010301030103010301030103010301010103010301030103010301030103010301030101010301030103010301030103010301030103010101030103010301030103010301030<	IDENTIFY<th colspan="6</td>

American Indian/Alaska Native	217	168	77.4	49	22.6	47	35	74.5	12	25.5
Asian	763	672	88.1	91	11.9	176	152	86.4	24	13.6
Black/African American	13,915	10,916	78.4	2,999	21.6	3,791	3,011	79.4	780	20.6
Hispanic/Latino ^c	10,893	9,250	84.9	1,643	15.1	2,896	2,449	84.6	447	15.4
Native Hawaiian/other Pacific Islander	83	63	75.9	20	24.1	14	11	78.6	3	21.4
White	8,690	7,135	82.1	1,555	17.9	2,365	1,958	82.8	407	17.2
Multiracial	795	650	81.8	145	18.2	150	125	83.3	25	16.7
Transmission category ^d										
Male-to-male sexual contact ^e	23,930	19,743	82.5	4,187	17.5	6,469	5,339	82.5	1,130	17.5
Injection drug use ^f	2,388	1,811	75.8	577	24.2	570	445	78.0	125	22.0
Male	1,301	981	75.4	320	24.6	333	261	78.5	71	21.5
Female	1,087	830	76.3	257	23.7	237	183	77.3	54	22.7
Male-to-male sexual contact ^e and injection drug use ^f	1,221	989	81.0	231	19.0	262	214	81.7	48	18.3
Heterosexual contact ^g	7,705	6,216	80.7	1,490	19.3	2,110	1,721	81.6	389	18.4
Male	2,282	1,835	80.4	447	19.6	636	518	81.4	118	18.6
Female	5,424	4,381	80.8	1,043	19.2	1,474	1,203	81.7	270	18.3
Total ^h	35,356	28,854	81.6	6,502	18.4	9,439	7,741	82.0	1,698	18.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after diagnosis of HIV infection. Data are for cases reported to CDC through June 2023, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Data are based on residence at time of diagnosis of HIV infection. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

^a"Transgender woman" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender. "Transgender man" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender. ^bAdditional gender identity examples include "bigender," "gender queer," and "two-spirit."

^cHispanic/Latino persons can be of any race.

^dTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^eIncludes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact). ^fIncludes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers). ^gHeterosexual contact with a person known to have, or with a risk factor for, HIV infection. ^hIncludes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2022 through March 2023—47 states and the District of Columbia (*preliminary*)

2022					2023 (January–March)					
Area of	Total diagnoses	≥1 CD4 test	or VL ts	No CD4 tes	or VL t	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
residence	No.	No.	%	No.	%	No.	No.	%	No.	%
Alabama	518	396	76.4	122	23.6	107	44	41.1	63	58.9
Alaska	38	34	89.5	4	10.5	6	5	83.3	1	16.7
Arizona	899	750	83.4	149	16.6	327	278	85.0	49	15.0
Arkansas	306	249	81.4	57	18.6	104	93	89.4	11	10.6
California	4,577	3,793	82.9	784	17.1	942	817	86.7	125	13.3
Colorado	429	361	84.1	68	15.9	111	96	86.5	15	13.5
Connecticut	225	188	83.6	37	16.4	47	37	78.7	10	21.3
Delaware	128	106	82.8	22	17.2	29	24	82.8	5	17.2
District of Columbia	188	160	85.1	28	14.9	26	23	88.5	3	11.5
Florida	4,513	3,753	83.2	760	16.8	1,699	1,427	84.0	272	16.0
Georgia	2,687	2,201	81.9	486	18.1	616	539	87.5	77	12.5
Hawaii	70	58	82.9	12	17.1	6	6	100	0	0.0
Illinois	1,270	1,061	83.5	209	16.5	273	235	86.1	38	13.9
Indiana	622	482	77.5	140	22.5	178	137	77.0	41	23.0
Iowa	120	110	91.7	10	8.3	45	43	95.6	2	4.4
Kansas	136	120	88.2	16	11.8	43	35	81.4	8	18.6
Kentucky	406	316	77.8	90	22.2	121	104	86.0	17	14.0
Louisiana	856	678	79.2	178	20.8	234	189	80.8	45	19.2
Maine	40	37	92.5	3	7.5	6	5	83.3	1	16.7
Maryland	745	642	86.2	103	13.8	177	161	91.0	16	9.0
Massachusetts	435	384	88.3	51	11.7	44	43	97.7	1	2.3
Michigan	631	543	86.1	88	13.9	188	154	81.9	34	18.1
Minnesota	262	225	85.9	37	14.1	87	77	88.5	10	11.5
Mississippi	426	226	53.1	200	46.9	86	64	74.4	22	25.6
Missouri	504	409	81.2	95	18.8	130	104	80.0	26	20.0

https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/vol-4-no-3/index.html

Montana	10	7	70.0	3	30.0	5	4	80.0	1	20.0
Nebraska	90	77	85.6	13	14.4	24	23	95.8	1	4.2
Nevada	533	473	88.7	60	11.3	134	115	85.8	19	14.2
New Hampshire	28	20	71.4	8	28.6	6	5	83.3	1	16.7
New Mexico	73	65	89.0	8	11.0	5	4	80.0	1	20.0
New York	2,205	1,917	86.9	288	13.1	602	522	86.7	80	13.3
North Carolina	1,360	1,092	80.3	268	19.7	367	292	79.6	75	20.4
North Dakota	10	7	70.0	3	30.0	1	1	100	0	0.0
Ohio	859	703	81.8	156	18.2	252	210	83.3	42	16.7
Oklahoma	392	315	80.4	77	19.6	65	53	81.5	12	18.5
Oregon	249	207	83.1	42	16.9	66	59	89.4	7	10.6
Rhode Island	66	62	93.9	4	6.1	14	13	92.9	1	7.1
South Carolina	770	615	79.9	155	20.1	285	246	86.3	39	13.7
South Dakota	39	27	69.2	12	30.8	14	13	92.9	1	7.1
Tennessee	861	609	70.7	252	29.3	248	162	65.3	86	34.7
Texas	4,840	3,760	77.7	1,080	22.3	1,227	849	69.2	378	30.8
Utah	151	122	80.8	29	19.2	35	29	82.9	6	17.1
Vermont	4	4	100	0	0.0	2	2	100	0	0.0
Virginia	831	683	82.2	148	17.8	209	183	87.6	26	12.4
Washington	511	450	88.1	61	11.9	135	122	90.4	13	9.6
West Virginia	139	85	61.2	54	38.8	28	16	57.1	12	42.9
Wisconsin	290	260	89.7	30	10.3	82	77	93.9	5	6.1
Wyoming	14	12	85.7	2	14.3	1	1	100	0	0.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through June 2023, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2022 through March 2023—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)

:	2022	2023 (Jan	uary–March)

	Total diagnoses	≥1 CD4 test	or VL s	No CD4 tes	l or VL st	Total diagnoses	Total≥1 CD4 or VLdiagnosestests		No CD4 or VL test	
Area of residence	No.	No.	%	No.	%	No.	No.	%	No.	%
Arizona										
Maricopa County	592	495	83.6	97	16.4	225	186	82.7	39	17.3
California										
Alameda County	201	176	87.6	25	12.4	55	47	85.5	8	14.5
Los Angeles County	1,429	1,172	82.0	257	18.0	312	269	86.2	43	13.8
Orange County	252	214	84.9	38	15.1	67	58	86.6	9	13.4
Riverside County	308	245	79.5	63	20.5	53	44	83.0	9	17.0
Sacramento County	190	159	83.7	31	16.3	34	31	91.2	3	8.8
San Bernardino County	281	199	70.8	82	29.2	54	40	74.1	14	25.9
San Diego County	378	313	82.8	65	17.2	33	32	97.0	1	3.0
San Francisco County	213	194	91.1	19	8.9	44	41	93.2	3	6.8
District of Columbia	188	160	85.1	28	14.9	26	23	88.5	3	11.5
Florida	!	!			!	!				
Broward County	608	491	80.8	117	19.2	239	199	83.3	40	16.7
Duval County	288	211	73.3	77	26.7	95	78	82.1	17	17.9
Hillsborough County	297	247	83.2	50	16.8	125	109	87.2	16	12.8
Miami-Dade County	1,096	920	83.9	176	16.1	429	352	82.1	77	17.9
Orange County	430	349	81.2	81	18.8	149	125	83.9	24	16.1
Palm Beach County	297	261	87.9	36	12.1	82	70	85.4	12	14.6
Pinellas County	116	100	86.2	16	13.8	54	42	77.8	12	22.2
Georgia										
Cobb County	199	170	85.4	29	14.6	48	43	89.6	5	10.4
DeKalb County	378	314	83.1	64	16.9	77	69	89.6	8	10.4
Fulton County	585	484	82.7	101	17.3	116	104	89.7	12	10.3
Gwinnett County	209	174	83.3	35	16.7	50	46	92.0	4	8.0
Illinois	!	!			!	!				
Cook County	853	719	84.3	134	15.7	177	155	87.6	22	12.4
Indiana										
Marion County	252	201	79.8	51	20.2	71	58	81.7	13	18.3
Louisiana										
East Baton Rouge Parish	132	114	86.4	18	13.6	34	29	85.3	5	14.7
Orleans Parish	126	104	82.5	22	17.5	33	27	81.8	6	18.2

Maryland

Baltimore City	157	138	87.9	19	12.1	41	40	97.6	1	2.4
Montgomery County	106	92	86.8	14	13.2	27	23	85.2	4	14.8
Prince George's County	253	221	87.4	32	12.6	51	45	88.2	6	11.8
Massachusetts										
Suffolk County	115	103	89.6	12	10.4	19	18	94.7	1	5.3
Michigan										
Wayne County	247	205	83.0	42	17.0	78	61	78.2	17	21.8
Nevada										
Clark County	487	432	88.7	55	11.3	121	105	86.8	16	13.2
New York										
Bronx County	394	336	85.3	58	14.7	99	77	77.8	22	22.2
Kings County	475	424	89.3	51	10.7	114	98	86.0	16	14.0
New York County	320	266	83.1	54	16.9	87	71	81.6	16	18.4
Queens County	368	329	89.4	39	10.6	100	91	91.0	9	9.0
North Carolina										
Mecklenburg County	279	224	80.3	55	19.7	84	71	84.5	13	15.5
Ohio										
Cuyahoga County	119	99	83.2	20	16.8	36	34	94.4	2	5.6
Franklin County	195	163	83.6	32	16.4	73	61	83.6	12	16.4
Hamilton County	94	81	86.2	13	13.8	29	24	82.8	5	17.2
Pennsylvania										
Philadelphia County	378	305	80.7	73	19.3	113	96	85.0	17	15.0
Tennessee										
Shelby County	338	221	65.4	117	34.6	91	47	51.6	44	48.4
Texas										
Bexar County	347	266	76.7	81	23.3	78	56	71.8	22	28.2
Dallas County	880	669	76.0	211	24.0	226	153	67.7	73	32.3
Harris County	1,275	995	78.0	280	22.0	360	246	68.3	114	31.7
Tarrant County	335	256	76.4	79	23.6	86	62	72.1	24	27.9
Travis County	243	209	86.0	34	14.0	56	38	67.9	18	32.1
Washington										
King County	267	241	90.3	26	9.7	66	60	90.9	6	9.1

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of \geq 1 CD4 or VL tests \leq 1 month after diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through June 2023, are

considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

Table 3a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2023, among persons aged ≥16 years, by selected characteristics—United States (*preliminary*)

		2019		2020 (0	COVID-19 pan	demic)	2021		
	Persons prescribed PrEPª	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEPª	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEPª	Persons with PrEP indications ^b	 CO \
	No.	No.	%	No.	No.	96	No.	No.	
Sex at birth									
Male	254,682	989,200	25.7	277,813	989,200	28.1	338,415	989,200	
Female	21,098	227,010	9.3	23,695	227,010	10.4	28,066	227,010	
Age (yr)									
16–24	36,981	246,290	15.0	38,421	246,290	15.6	47,981	246,290	
25-34	112,931	434,680	26.0	119,397	434,680	27.5	146,885	434,680	
35-44	64,021	238,470	26.8	72,344	238,470	30.3	88,734	238,470	
45-54	37,514	173,420	21.6	40,912	173,420	23.6	46,189	173,420	
≥55	24,476	123,350	19.8	30,502	123,350	24.7	36,973	123,350	
Race/ethnicity ^d									
Black/African American	37,478	468,540	8.0	43,478	468,540	9.3	51,887	468,540	
Hispanic/Latino ^e	45,533	312,820	14.6	51,432	312,820	16.4	64,073	312,820	
Other	12,294	131,180	9.4	12,819	131,180	9.8	15,731	131,180	
White	180,618	300,650	60.1	193,846	300,650	64.5	235,071	300,650	
Total	275,923	1,216,210	22.7	301,576	1,216,210	24.8	366,762	1,216,210	

		2022		2023 (January–March)				
	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c		
	No.	No.	%	No.	No.	%		
Sex at birth								
Male	405,189	989,200	41.0	285,069	989,200	28.8		
Female	32,854	227,010	14.5	18,475	227,010	8.1		
Age (yr)								

16–24	57,992	246,290	23.5	27,383	246,290	11.1				
25–34	172,325	434,680	39.6	113,294	434,680	26.1				
35–44	109,030	238,470	45.7	84,135	238,470	35.3				
45-54	53,520	173,420	30.9	41,611	173,420	24.0				
≥55	45,297	123,350	36.7	37,193	123,350	30.2				
Race/ethnicity ^d										
Black/African American	60,056	468,540	12.8	39,202	468,540	8.4				
Hispanic/Latino ^e	76,481	312,820	24.4	51,853	312,820	16.6				
Other	19,130	131,180	14.6	13,255	131,180	10.1				
White	282,494	300,650	94.0	199,306	300,650	66.3				
Total	438,164	1,216,210	36.0	303,616	1,216,210	25.0				

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

^a Estimated by using data from IQVIA pharmacy database reported through March 2023 based on an algorithm that included FDAapproved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

^b Estimated by using 2018 data from National HIV Surveilance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2019–2023 PrEP coverage data.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

^d Race/ethnicity data were only available for <40% of persons prescribed PrEP each year. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.

^e Hispanic/Latino persons can be of any race.

Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2023, among persons aged ≥16 years, by area of residence—United States and Puerto Rico *(preliminary)*

		2019		2020 (0	COVID-19 pan	demic)	2021		
	Persons prescribed PrEP ^a	ns Persons bed with PrEP Pr a indications ^b cove		Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEPª	Persons with PrEP indications ^b	PrE covera
	No.	No.	%	No.	No.	96	No.	No.	%
Alabama	1,834	11,020	16.6	1,910	11,020	17.3	2,762	11,020	

Alaska	227	1,780	12.8	242	1,780	13.6	306	1,780	
Arizona	4,587	25,780	17.8	5,069	25,780	19.7	6,587	25,780	
Arkansas	728	5,130	14.2	865	5,130	16.9	1,273	5,130	
California	41,745	165,030	25.3	42,395	165,030	25.7	50,398	165,030	
Colorado	4,398	25,120	17.5	4,809	25,120	19.1	6,188	25,120	
Connecticut	2,675	9,560	28.0	2,473	9,560	25.9	3,046	9,560	
Delaware	484	4,400	11.0	481	4,400	10.9	652	4,400	
District of Columbia	5,922	12,950	45.7	6,014	12,950	46.4	6,828	12,950	
Florida	21,914	125,330	17.5	34,717	125,330	27.7	42,794	125,330	
Georgia	8,688	39,030	22.3	9,799	39,030	25.1	12,199	39,030	
Hawaii	820	4,360	18.8	904	4,360	20.7	1,136	4,360	
Idaho	481	4,790	10.0	662	4,790	13.8	880	4,790	
Illinois	16,661	55,860	29.8	15,991	55,860	28.6	18,436	55,860	
Indiana	2,986	22,170	13.5	3,194	22,170	14.4	4,239	22,170	
Iowa	1,409	4,760	29.6	1,550	4,760	32.6	1,948	4,760	
Kansas	905	5,060	17.9	952	5,060	18.8	1,279	5,060	
Kentucky	1,609	12,990	12.4	1,664	12,990	12.8	2,223	12,990	
Louisiana	3,912	15,920	24.6	3,568	15,920	22.4	4,151	15,920	
Maine	649	3,950	16.4	668	3,950	16.9	905	3,950	
Maryland	4,935	27,300	18.1	4,814	27,300	17.6	5,807	27,300	
Massachusetts	9,327	24,900	37.5	9,402	24,900	37.8	10,170	24,900	
Michigan	4,323	29,570	14.6	4,634	29,570	15.7	5,868	29,570	
Minnesota	4,201	21,720	19.3	4,209	21,720	19.4	5,258	21,720	
Mississippi	946	4,530	20.9	1,095	4,530	24.2	1,595	4,530	
Missouri	3,468	18,370	18.9	3,565	18,370	19.4	4,168	18,370	
Montana	266	2,290	11.6	292	2,290	12.8	391	2,290	
Nebraska	617	2,180	28.3	714	2,180	32.8	999	2,180	
Nevada	2,195	11,390	19.3	2,510	11,390	22.0	4,883	11,390	
New Hampshire	611	3,020	20.2	644	3,020	21.3	796	3,020	
New Jersey	5,714	25,280	22.6	5,928	25,280	23.4	7,294	25,280	
New Mexico	1,075	6,800	15.8	1,235	6,800	18.2	1,598	6,800	
New York	35,616	72,640	49.0	34,442	72,640	47.4	39,365	72,640	
North Carolina	5,413	32,490	16.7	6,163	32,490	19.0	7,944	32,490	
North Dakota	185	1,520	12.2	180	1,520	11.8	245	1,520	
Ohio	6,110	40,320	15.2	6,810	40,320	16.9	8,464	40,320	
Oklahoma	1,160	11,030	10.5	1,535	11,030	13.9	2,323	11,030	
Oregon	3,402	19,750	17.2	3,822	19,750	19.4	4,681	19,750	

Pennsylvania	10,104	36,490	27.7	10,582	36,490	29.0	13,059	36,490	
Puerto Rico	330	9,700	3.4	370	9,700	3.8	610	9,700	
Rhode Island	1,089	3,880	28.1	1,163	3,880	30.0	1,518	3,880	
South Carolina	1,725	10,390	16.6	2,102	10,390	20.2	2,927	10,390	
South Dakota	150	910	16.5	141	910	15.5	217	910	
Tennessee	3,898	22,460	17.4	5,165	22,460	23.0	7,224	22,460	
Texas	23,192	123,790	18.7	27,564	123,790	22.3	34,776	123,790	
Utah	2,036	6,840	29.8	2,360	6,840	34.5	3,251	6,840	
Vermont	336	1,060	31.7	317	1,060	29.9	476	1,060	
Virginia	4,403	31,430	14.0	5,118	31,430	16.3	6,271	31,430	
Washington	9,920	40,050	24.8	10,097	40,050	25.2	11,402	40,050	
West Virginia	569	5,250	10.8	523	5,250	10.0	706	5,250	
Wisconsin	2,473	12,980	19.1	2,527	12,980	19.5	2,815	12,980	
Wyoming	93	890	10.4	95	890	10.7	135	890	

		2022		2023 (January–March)			
	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	
	No.	No.	%	No.	No.	%	
Alabama	3,443	11,020	31.2	2,410	11,020	21.9	
Alaska	401	1,780	22.5	253	1,780	14.2	
Arizona	8,339	25,780	32.3	6,041	25,780	23.4	
Arkansas	1,678	5,130	32.7	1,147	5,130	22.4	
California	61,758	165,030	37.4	42,824	165,030	25.9	
Colorado	7,607	25,120	30.3	5,190	25,120	20.7	
Connecticut	4,003	9,560	41.9	2,663	9,560	27.9	
Delaware	841	4,400	19.1	637	4,400	14.5	
District of Columbia	7,729	12,950	59.7	5,636	12,950	43.5	
Florida	46,471	125,330	37.1	32,083	125,330	25.6	
Georgia	13,755	39,030	35.2	9,419	39,030	24.1	
Hawaii	1,510	4,360	34.6	1,040	4,360	23.9	
Idaho	1,073	4,790	22.4	674	4,790	14.1	
Illinois	21,936	55,860	39.3	16,167	55,860	28.9	
Indiana	5,456	22,170	24.6	3,885	22,170	17.5	
Iowa	2,201	4,760	46.2	1,492	4,760	31.3	
Kansas	1,602	5,060	31.7	1,119	5,060	22.1	
Kentucky	3,029	12,990	23.3	2,145	12,990	16.5	

Louisiana	4,743	15,920	29.8	3,264	15,920	20.5
Maine	1,125	3,950	28.5	765	3,950	19.4
Maryland	6,892	27,300	25.2	4,712	27,300	17.3
Massachusetts	13,022	24,900	52.3	8,783	24,900	35.3
Michigan	7,138	29,570	24.1	4,723	29,570	16.0
Minnesota	6,580	21,720	30.3	4,593	21,720	21.1
Mississippi	1,736	4,530	38.3	1,042	4,530	23.0
Missouri	5,140	18,370	28.0	3,664	18,370	19.9
Montana	533	2,290	23.3	349	2,290	15.2
Nebraska	1,272	2,180	58.3	901	2,180	41.3
Nevada	5,687	11,390	49.9	3,282	11,390	28.8
New Hampshire	1,035	3,020	34.3	737	3,020	24.4
New Jersey	8,938	25,280	35.4	6,255	25,280	24.7
New Mexico	2,034	6,800	29.9	1,466	6,800	21.6
New York	46,019	72,640	63.4	32,263	72,640	44.4
North Carolina	9,985	32,490	30.7	6,776	32,490	20.9
North Dakota	337	1,520	22.2	221	1,520	14.5
Ohio	10,344	40,320	25.7	7,311	40,320	18.1
Oklahoma	2,778	11,030	25.2	1,649	11,030	15.0
Oregon	6,058	19,750	30.7	4,098	19,750	20.7
Pennsylvania	16,086	36,490	44.1	11,407	36,490	31.3
Puerto Rico	821	9,700	8.5	558	9,700	5.8
Rhode Island	1,827	3,880	47.1	1,340	3,880	34.5
South Carolina	3,654	10,390	35.2	2,581	10,390	24.8
South Dakota	321	910	35.3	207	910	22.7
Tennessee	8,865	22,460	39.5	5,762	22,460	25.7
Texas	40,726	123,790	32.9	28,720	123,790	23.2
Utah	4,011	6,840	58.6	2,841	6,840	41.5
Vermont	573	1,060	54.1	370	1,060	34.9
Virginia	7,560	31,430	24.1	5,294	31,430	16.8
Washington	13,760	40,050	34.4	9,416	40,050	23.5
West Virginia	913	5,250	17.4	586	5,250	11.2
Wisconsin	3,344	12,980	25.8	2,235	12,980	17.2
Wyoming	183	890	20.6	130	890	14.6

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

^a Estimated by using data from IQVIA pharmacy database reported through March 2023 based on an algorithm that included FDAapproved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

^b Estimated by using 2018 data from National HIV Surveilance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2019–2023 PrEP coverage data.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2023, among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)

		2019			COVID-19 pan	demic)	2021	
	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEPª	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEPª	Persons with PrEP indications ^b
	No.	No.	%	No.	No.	%	No.	No.
Arizona								
Maricopa County	3,544	22,720	15.6	3,904	22,720	17.2	5,041	22,720
California								
Alameda County	2,172	8,930	24.3	2,012	8,930	22.5	2,212	8,930
Los Angeles County	13,781	67,450	20.4	14,812	67,450	22.0	18,559	67,450
Orange County	2,029	10,510	19.3	2,197	10,510	20.9	2,830	10,510
Riverside County	1,818	11,080	16.4	1,954	11,080	17.6	2,565	11,080
Sacramento County	954	5,920	16.1	983	5,920	16.6	1,108	5,920
San Bernardino County	757	11,890	6.4	815	11,890	6.9	1,195	11,890
San Diego County	3,742	14,500	25.8	3,807	14,500	26.3	4,440	14,500
San Francisco County	8,838	10,840	81.5	8,154	10,840	75.2	8,226	10,840
District of Columbia	5,922	12,950	45.7	6,014	12,950	46.4	6,828	12,950
Florida								
Broward County	3,881	20,470	19.0	6,847	20,470	33.4	8,400	20,470
Duval County	500	8,970	5.6	723	8,970	8.1	883	8,970
Hillsborough County	1,394	12,910	10.8	1,539	12,910	11.9	2,068	12,910
Miami-Dade County	6,500	21,760	29.9	10,248	21,760	47.1	11,434	21,760

Orange County	2,795	15,310	18.3	3,908	15,310	25.5	4,761	15,310
Palm Beach County	894	9,170	9.7	3,013	9,170	32.9	2,767	9,170
Pinellas County	1,157	9,530	12.1	1,245	9,530	13.1	1,675	9,530
Georgia								
Cobb County	569	3,070	18.5	656	3,070	21.4	811	3,070
DeKalb County	1,545	6,290	24.6	1,692	6,290	26.9	2,025	6,290
Fulton County	3,314	13,120	25.3	3,620	13,120	27.6	4,295	13,120
Gwinnett County	684	3,240	21.1	797	3,240	24.6	1,002	3,240
Illinois								
Cook County	13,646	39,060	34.9	12,925	39,060	33.1	14,802	39,060
Indiana								
Marion County	1,152	9,150	12.6	1,209	9,150	13.2	1,583	9,150
Louisiana								
East Baton Rouge Parish	492	1,810	27.2	531	1,810	29.3	589	1,810
Orleans Parish	1,518	4,590	33.1	1,330	4,590	29.0	1,521	4,590
Maryland								
Baltimore City	904	6,330	14.3	846	6,330	13.4	978	6,330
Montgomery County	896	5,770	15.5	897	5,770	15.5	1,153	5,770
Prince George's County	798	4,040	19.8	824	4,040	20.4	992	4,040
Massachusetts								
Suffolk County	2,768	6,520	42.5	2,808	6,520	43.1	2,812	6,520
Michigan								
Wayne County	1,203	9,270	13.0	1,222	9,270	13.2	1,549	9,270
Nevada								
Clark County	1,876	11,670	16.1	2,111	11,670	18.1	4,294	11,670
New Jersey								
Essex County	687	4,090	16.8	718	4,090	17.6	845	4,090
Hudson County	1,072	4,650	23.1	1,074	4,650	23.1	1,303	4,650
New York								
Bronx County	2,254	5,570	40.5	2,084	5,570	37.4	2,128	5,570
Kings County	7,654	15,650	48.9	7,498	15,650	47.9	8,941	15,650
New York County	14,278	15,540	91.9	13,873	15,540	89.3	15,868	15,540
Queens County	3,886	9,230	42.1	3,825	9,230	41.4	4,301	9,230
North Carolina								
Mecklenburg County	1,336	8,450	15.8	1,571	8,450	18.6	1,959	8,450
Ohio		!		!		!		
Cuyahoga County	952	7,520	12.7	962	7,520	12.8	1,262	7,520

Franklin County	2,043	11,620	17.6	2,304	11,620	19.8	2,737	11,620
Hamilton County	564	7,720	7.3	637	7,720	8.3	817	7,720
Pennsylvania								
Philadelphia County	3,663	9,840	37.2	3,529	9,840	35.9	4,069	9,840
Puerto Rico								
San Juan Municipio	d	2,190	n/a	d	2,190	n/a	63	2,190
Tennessee								
Shelby County	636	6,450	9.9	817	6,450	12.7	946	6,450
Texas								
Bexar County	1,536	11,920	12.9	1,780	11,920	14.9	2,352	11,920
Dallas County	4,125	28,670	14.4	5,172	28,670	18.0	6,573	28,670
Harris County	4,960	40,670	12.2	6,012	40,670	14.8	7,495	40,670
Tarrant County	1,456	11,340	12.8	1,634	11,340	14.4	2,102	11,340
Travis County	4,524	11,590	39.0	5,045	11,590	43.5	5,765	11,590
Washington								
King County	6,921	17,890	38.7	6,988	17,890	39.1	7,649	17,890

	2022			2023 (January–March)			
	Persons prescribed PrEPª	Persons with PrEP indications ^b	PrEP coverage ^c	Persons prescribed PrEPª	Persons with PrEP indications ^b	PrEP coverage ^c	
	No.	No.	%	No.	No.	%	
Arizona							
Maricopa County	6,406	22,720	28.2	4,655	22,720	20.5	
California							
Alameda County	2,711	8,930	30.4	1,761	8,930	19.7	
Los Angeles County	23,462	67,450	34.8	16,567	67,450	24.6	
Orange County	3,333	10,510	31.7	2,290	10,510	21.8	
Riverside County	3,230	11,080	29.2	2,408	11,080	21.7	
Sacramento County	1,375	5,920	23.2	940	5,920	15.9	
San Bernardino County	1,560	11,890	13.1	1,028	11,890	8.6	
San Diego County	5,395	14,500	37.2	3,743	14,500	25.8	
San Francisco County	9,100	10,840	83.9	6,483	10,840	59.8	
District of Columbia	7,729	12,950	59.7	5,636	12,950	43.5	
Florida							
Broward County	8,083	20,470	39.5	5,633	20,470	27.5	
Duval County	1,500	8,970	16.7	1,242	8,970	13.8	

Hillsborough County	2,624	12,910	20.3	1,864	12,910	14.4
Miami-Dade County	11,265	21,760	51.8	7,850	21,760	36.1
Orange County	5,806	15,310	37.9	4,257	15,310	27.8
Palm Beach County	2,474	9,170	27.0	1,502	9,170	16.4
Pinellas County	2,137	9,530	22.4	1,545	9,530	16.2
Georgia						
Cobb County	920	3,070	30.0	622	3,070	20.3
DeKalb County	2,231	6,290	35.5	1,538	6,290	24.5
Fulton County	4,702	13,120	35.8	3,275	13,120	25.0
Gwinnett County	1,136	3,240	35.1	756	3,240	23.3
Illinois						
Cook County	17,275	39,060	44.2	12,863	39,060	32.9
Indiana						
Marion County	2,000	9,150	21.9	1,524	9,150	16.7
Louisiana						
East Baton Rouge Parish	622	1,810	34.4	408	1,810	22.5
Orleans Parish	1,679	4,590	36.6	1,174	4,590	25.6
Maryland						
Baltimore City	1,136	6,330	17.9	770	6,330	12.2
Montgomery County	1,459	5,770	25.3	1,024	5,770	17.7
Prince George's County	1,085	4,040	26.9	753	4,040	18.6
Massachusetts						
Suffolk County	3,597	6,520	55.2	2,406	6,520	36.9
Michigan						
Wayne County	1,861	9,270	20.1	1,199	9,270	12.9
Nevada						
Clark County	4,356	11,670	37.3	2,367	11,670	20.3
New Jersey						
Essex County	1,016	4,090	24.8	715	4,090	17.5
Hudson County	1,601	4,650	34.4	1,157	4,650	24.9
New York						
Bronx County	2,168	5,570	38.9	1,376	5,570	24.7
Kings County	10,458	15,650	66.8	7,431	15,650	47.5
New York County	18,162	15,540	116.9	13,043	15,540	83.9
Queens County	5,219	9,230	56.5	3,601	9,230	39.0
North Carolina				ļ	!	
Mecklenburg County	2,329	8,450	27.6	1,594	8,450	18.9

Ohio										
Cuyahoga County	1,679	7,520	22.3	1,248	7,520	16.6				
Franklin County	3,118	11,620	26.8	2,227	11,620	19.2				
Hamilton County	987	7,720	12.8	684	7,720	8.9				
Pennsylvania	Pennsylvania									
Philadelphia County	5,029	9,840	51.1	3,578	9,840	36.4				
Puerto Rico										
San Juan Municipio	117	2,190	5.3	83	2,190	3.8				
Tennessee										
Shelby County	1,166	6,450	18.1	811	6,450	12.6				
Texas										
Bexar County	2,858	11,920	24.0	2,087	11,920	17.5				
Dallas County	7,216	28,670	25.2	5,117	28,670	17.8				
Harris County	8,695	40,670	21.4	6,050	40,670	14.9				
Tarrant County	2,498	11,340	22.0	1,755	11,340	15.5				
Travis County	6,574	11,590	56.7	4,787	11,590	41.3				
Washington										
King County	9,013	17,890	50.4	6,303	17,890	35.2				

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

^a Estimated by using data from IQVIA pharmacy database reported through March 2023 based on an algorithm that included FDAapproved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total. ^b Estimated by using 2018 data from National HIV Surveilance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a

numerator. In this table, 2018 denominators were used for 2019–2023 PrEP coverage data.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

^d Data value <40 was not reported due to unreliability.

Table 4. Ending the HIV Epidemic Phase I jurisdictions

Jurisdictions	Territories	States
Arizona	Puerto Rico ^a	Alabama
Maricopa County		Arkansas Kontusku
California	San Juan Municipioª	Mississippi
		Missouri
Alameda County		Oklahoma South Carolina
Los Angeles County		
Orange County		
Riverside County		
Sacramento County		
San Bernardino County		
San Diego County		
San Francisco County		
District of Columbia		
Florida		
Broward County		
Duval County		
Hillsborough County		
Miami-Dade County		
Orange County		
Palm Beach County		
Pinellas County		
Coordia		
Georgia		
Cobb County		
DeKalb County		
Fulton County		
Gwinnett County		
Illinois		
Cook County		
Indiana		
Marion County		
Louisiana		
East Baton Rouge Parish		
Orleans Parish		

me 4, Number 3 HIV Surveillance Data Ta	bies Reports Resource Libra
Maryland	
Baltimore City	
Montgomery County	
Prince George's County	
Massachusetts	
Suffolk County	
Michigan	
Wayne County	
Nevada	
Clark County	
New Jersey ^a	
Essex County	
Hudson County	
New York	
Bronx County	
Kings County	
New York County	
Queens County	
North Carolina	
Mecklenburg County	
Ohio	
Cuyahoga County	
Franklin County	
Hamilton County	
Pennsylvania	

Pennsylvania

Philadelphia County

Tennessee

Shelby County

Texas

	Bexar County	
	Dallas County	
	Harris County	
	Tarrant County	
	Travis County	
Was	hington	
	King County	

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. For more information on the Ending the HIV Epidemic in the U.S. initiative, see https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview

^a Linkage to care and viral suppression data are not provided for states and associated jurisdictions that have incomplete reporting of laboratory data to CDC: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

Last Reviewed: October 17, 2023 Source: Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention